Abcellera Biologics Inc. (ABCL) Stock Price & Analysis

Abcellera Biologics Inc. (ABCL) fell 1.21% to USD 11.43 as of September 8, 2026 at 06:21 UTC, according to Nexqual real-time market data.

ABCL last closed at USD 11.43; the session ranged USD 11.33–11.59 on volume of 2,019,253 shares. Market capitalization is —, with a 52-week range of USD 2.75–12.58 (NMS). Source: Nexqual, September 8, 2026 at 06:21 UTC.

Key Statistics (as of September 8, 2026 at 06:21 UTC)

Technical Analysis (ABCL)

Nexqual's technical model rates ABCL "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 06:21 UTC.

From Abcellera Biologics Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Platform We have invested approximately $1 billion over nearly 15 years to build a differentiated and vertically-integrated antibody drug platform.
• We anticipate initiating Phase 1/2 clinical trials for ABCL688 and ABCL386 in 2027. • Opened our clinical manufacturing facility , which completes a multi-year investment to build our integrated platform for creating antibody medicines.
• Our integrated platform for antibody drug discovery and development We discover antibodies from natural immune responses, which are pre-enriched for antibodies with higher target-binding specificity and developability than those generated by synthetic methods.
• Our competitive advantage consists not of a single proprietary technology, but of the integration of proprietary know-how, specialized multidisciplinary teams, and the physical infrastructure necessary to advance programs from target to the clinic.

Partnerships

• We discovered ABCL575 during our collaboration with EQRx Inc. ("EQRx") as part of a co-development program that began in 2021.
• In late 2023, with our platform near complete, we committed to transitioning from a partnership model to a clinical-stage biotechnology company developing our own pipeline of drug candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:21 UTC. This page is informational and not investment advice.